Skip to main content
Erschienen in: Journal of Cancer Education 4/2012

01.12.2012

Understanding the Limits of Large Datasets

verfasst von: Catherine M. Sanders, Sidney L. Saltzstein, Matthew M. Schultzel, Duy H. Nguyen, Helen Shi Stafford, Georgia Robins Sadler

Erschienen in: Journal of Cancer Education | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Many health professionals use large datasets to answer behavioral, translational, or clinical questions. Understanding the impact of missing data in large databases, such as disease registries, can avoid erroneous interpretations of these data. Using the California Cancer Registry, the authors selected seven common cancers, seven sociodemographic and clinical variables, and the top three reporting sources, as examples of the type of data that would be deemed critical to most studies. The gender variable had no missing data, followed by age (<0.1 % missing), ethnicity (1.7 %), stage (9.8 %), differentiation (39.1 %), and birthplace (41.1 %). Reports from hospitals and clinics had the lowest percentages of missing data. Users of large datasets should anticipate the limitations of missing data to prevent methodological flaws and misinterpretations of research findings. Knowledge of what and how much data may be missing in large datasets can help prevent errors in research conclusions, while better guiding treatment modalities and public health policies and programs.
Literatur
1.
Zurück zum Zitat American Joint Committee on Cancer (1988) Manual for staging of cancer, Thirdth edn. J.B. Lippincott, Philadelphia American Joint Committee on Cancer (1988) Manual for staging of cancer, Thirdth edn. J.B. Lippincott, Philadelphia
2.
Zurück zum Zitat Furie B et al (2003) Clinical hematology and oncology. Presentation, diagnosis, and treatment. Churchill Livingstone, Philadelphia Furie B et al (2003) Clinical hematology and oncology. Presentation, diagnosis, and treatment. Churchill Livingstone, Philadelphia
3.
Zurück zum Zitat Gomez SL, Glaser SL (2005) Quality of cancer registry birthplace data for Hispanics living in the United States. Cancer Causes Control 16(6):713–723PubMedCrossRef Gomez SL, Glaser SL (2005) Quality of cancer registry birthplace data for Hispanics living in the United States. Cancer Causes Control 16(6):713–723PubMedCrossRef
4.
Zurück zum Zitat Gomez SL et al (2004) Bias in completeness of birthplace data for Asian groups in a population-based cancer registry (United States). Cancer Causes Control 15(3):243–253PubMedCrossRef Gomez SL et al (2004) Bias in completeness of birthplace data for Asian groups in a population-based cancer registry (United States). Cancer Causes Control 15(3):243–253PubMedCrossRef
5.
Zurück zum Zitat Lin SS, O'Malley CD, Lui SW (2001) Factors associated with missing birthplace information in a population-based cancer registry. Ethn Dis 11(4):598–605PubMed Lin SS, O'Malley CD, Lui SW (2001) Factors associated with missing birthplace information in a population-based cancer registry. Ethn Dis 11(4):598–605PubMed
6.
Zurück zum Zitat Gomez SL et al (2003) Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health 93(10):1685–1688PubMedCrossRef Gomez SL et al (2003) Hospital policy and practice regarding the collection of data on race, ethnicity, and birthplace. Am J Public Health 93(10):1685–1688PubMedCrossRef
7.
Zurück zum Zitat Konowitz PM, Petrossian GA, Rose DN (1984) The underreporting of disease and physicians' knowledge of reporting requirements. Public Health Rep 99(1):31–35PubMed Konowitz PM, Petrossian GA, Rose DN (1984) The underreporting of disease and physicians' knowledge of reporting requirements. Public Health Rep 99(1):31–35PubMed
8.
Zurück zum Zitat Seixas NS, Rosenman KD (1986) Voluntary reporting system for occupational disease: pilot project, evaluation. Public Health Rep 101(3):278–282PubMed Seixas NS, Rosenman KD (1986) Voluntary reporting system for occupational disease: pilot project, evaluation. Public Health Rep 101(3):278–282PubMed
9.
Zurück zum Zitat Mettlin CJ et al (1997) A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer 79(10):2052–2061PubMedCrossRef Mettlin CJ et al (1997) A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer 79(10):2052–2061PubMedCrossRef
Metadaten
Titel
Understanding the Limits of Large Datasets
verfasst von
Catherine M. Sanders
Sidney L. Saltzstein
Matthew M. Schultzel
Duy H. Nguyen
Helen Shi Stafford
Georgia Robins Sadler
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Education / Ausgabe 4/2012
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-012-0383-7

Weitere Artikel der Ausgabe 4/2012

Journal of Cancer Education 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.